Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 76Urinary Bladder Neoplasms 20Neoplasms 11Carcinoma, Transitional Cell 8Non-Muscle Invasive Bladder Neoplasms 6Lung Neoplasms 6Carcinoma, Renal Cell 6Neoplasm Metastasis 5Breast Neoplasms 4Testicular Neoplasms 3Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Kidney Neoplasms 3Colorectal Neoplasms 3Carcinoma in Situ 3Adenocarcinoma 3Acute Kidney Injury 3Uterine Cervical Neoplasms 2Prostate CA 2Melanoma 2Liver Neoplasms 2Kidney Failure, Chronic 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Critical Illness 2Colonic Neoplasms 2Agnosia 2

Interventions

relatlimab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Muscle Invasive Bladder Urothelial Carcinoma × Genitourinary × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡